Literature DB >> 25563375

Antioxidant defense system in prostate adenocarcinoma and benign prostate hyperplasia of elderly patients.

K Szewczyk-Golec, J Tyloch, J Czuczejko.   

Abstract

UNLABELLED: Prostate adenocarcinoma (PC) and benign prostate hyperplasia (BPH) are age-related diseases. The augmented oxidative stress is suggested to play an important role in the pathogenesis of both mentioned prostate disorders. In the presented study the antioxidant defense system in PC and BPH patients has been evaluated. The study was carried out on 30 PC patients (age 61±8 years) and 30 BPH patients (age 63±8 years). The control group consisted of 25 healthy men (age 61±14 years). The reduced glutathione (GSH) concentrations in the erythrocytes and the activities of plasma superoxide dismutase (EC-SOD), plasma glutathione peroxidase (GPx-3), erythrocyte glutathione peroxidase (GPx-1) and erythrocyte glutathione S-transferase (GST) were measured in the examined groups. GSH concentrations in the erythrocytes and plasma GPx-3 activities in the PC group (2.31±0.27 mmol/l and 186.2±39 U/l, respectively) were significantly lower (P<0.05) as compared with the control group (2.52±0.24 and 211.8±26, respectively) and the BPH group (2.45±0.27 and 206.6±48, respectively). Erythrocyte GPx-1 activities in the BPH patients (14.76±3.5 U/g Hb) were statistically decreased (P<0.05) than in the healthy people (16.94±3.7) and in the PC patients (16.82±3.7). There were no significant differences in the activities of GST and EC-SOD between the PC group (2.72±1.34 nmol CDNB-GSH/mg Hb/min and 19.33±4.4 U/ml, respectively), the BPH group (2.53±1.00 and 19.22±4.8, respectively) and the controls (2.88±0.82 and 19.40±4.1, respectively). These results indicate that antioxidant defense system is decreased in the elderly patients with PC and BPH. The differences in the antioxidative system between examined groups of patients may suggest the different etiologies of both diseases. KEYWORDS: antioxidative enzymes, antioxidant defense system, glutathione, benign prostate hyperplasia, prostate adenocarcinoma.

Entities:  

Year:  2015        PMID: 25563375     DOI: 10.4149/neo_2015_015

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

Review 1.  Precision intervention for prostate cancer: Re-evaluating who is at risk.

Authors:  Alexandros Papachristodoulou; Cory Abate-Shen
Journal:  Cancer Lett       Date:  2022-04-29       Impact factor: 9.756

Review 2.  Oxidative stress in prostate hyperplasia and carcinogenesis.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2016-09-08

Review 3.  Prostate Cancer Disparity, Chemoprevention, and Treatment by Specific Medicinal Plants.

Authors:  Clement G Yedjou; Ariane T Mbemi; Felicite Noubissi; Solange S Tchounwou; Nole Tsabang; Marinelle Payton; Lucio Miele; Paul B Tchounwou
Journal:  Nutrients       Date:  2019-02-04       Impact factor: 5.717

4.  Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet.

Authors:  Yongzhi Li; Benkang Shi; Fengming Dong; Xingwang Zhu; Bing Liu; Yili Liu
Journal:  Aging (Albany NY)       Date:  2019-08-14       Impact factor: 5.682

Review 5.  The Involvement of the Oxidative Stress Status in Cancer Pathology: A Double View on the Role of the Antioxidants.

Authors:  Kamal Fatima Zahra; Radu Lefter; Ahmad Ali; Ech-Chahad Abdellah; Constantin Trus; Alin Ciobica; Daniel Timofte
Journal:  Oxid Med Cell Longev       Date:  2021-08-05       Impact factor: 6.543

6.  Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients.

Authors:  George Awuku Asare; Sabina Ekua Andam; Henry Asare-Anane; Seth Ammanquah; Yvonne Anang-Quartey; Daniel K Afriyie; Iddis Musah
Journal:  Prostate Int       Date:  2017-04-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.